GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Buyback Yield %

Spectral AI (Spectral AI) Buyback Yield % : -9.19 (As of Jun. 01, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Spectral AI's current buyback yield was -9.19%.

Spectral AI Buyback Yield % Historical Data

The historical data trend for Spectral AI's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Buyback Yield % Chart

Spectral AI Annual Data
Trend Dec21 Dec22 Dec23
Buyback Yield %
- - -8.36

Spectral AI Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial - - - - -28.65

Competitive Comparison of Spectral AI's Buyback Yield %

For the Medical Devices subindustry, Spectral AI's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral AI's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Spectral AI's Buyback Yield % falls into.


Spectral AI Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Spectral AI's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.351) / 40.085454
=-8.36%

Spectral AI's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 2.667) * 4 / 37.237299
=-28.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.

Spectral AI Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Spectral AI's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Buyback Yield %
Comparable Companies
RPID RWLK DCTH MOVE ECOR BSGM ICCM EAR SRTS IRIX ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201
Website
https://www.spectralmd.com
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.
Executives
John Michael Dimaio 10 percent owner 6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p. 10 percent owner 2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton director RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b. director 13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher officer: Chief Scientist 6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler officer: Chief Financial Officer 8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan director, officer: CHIEF EXECUTIVE OFFICER 3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone officer: GENERAL COUNSEL 1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos officer: CHIEF OPERATING OFFICER 5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai director 10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr. director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg 10 percent owner 73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260